A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...

Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $1.22 which represents a decrease of $-0.02 or -1.61% from the prior close of $1.24. The stock opened at $1.26 and touched a low of $1 ...

Editas Medicine Inc (EDIT) stock saw a modest uptick, ending the day at $1.22 which represents a slight increase of $0.08 or 7.02% from the prior close of $1.14. The stock opened at $1.2 and touched a ...

Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Editas Medicine (EDIT – Research Report) yesterday and set a ...

Editas Medicine has decided to end the development of its gene-editing therapy for thalassaemia and sickle cell disease (SCD), narrowing its R&D focus and making sweeping cuts to its workforce.

After hours: January 17 at 7:52:24 PM EST Loading Chart for EDIT ...

After hours: January 17 at 7:52:24 p.m. EST ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

DNA Ginkgo Bioworks Holdings, Inc.

Residential lot developer Forestar Group (NYSE: FOR) experienced a significant decline in its stock value, falling as much as 6.7% on Tuesday. The drop came after ...